Reviewing Alliqua BioMedical (ALQA) and Sientra (SIEN)
Alliqua BioMedical (NASDAQ: ALQA) and Sientra (NASDAQ:SIEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Earnings and Valuation
This table compares Alliqua BioMedical and Sientra’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Alliqua BioMedical||$18.24 million||1.01||-$28.24 million||($12.30)||-0.30|
|Sientra||$20.73 million||13.53||-$40.16 million||($2.66)||-5.46|
Alliqua BioMedical has higher revenue, but lower earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Alliqua BioMedical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
77.6% of Sientra shares are held by institutional investors. 15.8% of Alliqua BioMedical shares are held by company insiders. Comparatively, 28.1% of Sientra shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Alliqua BioMedical has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Sientra has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500.
This table compares Alliqua BioMedical and Sientra’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Alliqua BioMedical and Sientra, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alliqua BioMedical presently has a consensus price target of $14.17, suggesting a potential upside of 284.96%. Sientra has a consensus price target of $13.75, suggesting a potential downside of 5.37%. Given Alliqua BioMedical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Alliqua BioMedical is more favorable than Sientra.
Sientra beats Alliqua BioMedical on 9 of the 13 factors compared between the two stocks.
About Alliqua BioMedical
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.
Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.